HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Clinical trials for HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Triple-Drug attack shows promise for Hard-to-Treat breast cancer
Disease control Recruiting nowThis study is for people with a type of advanced breast cancer called HR+/HER2-negative. It tests a new drug, VS-6766, combined with two standard drugs (abemaciclib and fulvestrant). The goal is to find the safest dose and see if the combination can shrink tumors or stop them fro…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Adrienne G. Waks • Aim: Disease control
Last updated Jun 22, 2026 12:07 UTC
-
New combo therapy aims to slow advanced breast cancer in BRCA patients
Disease control Recruiting nowThis study tests whether adding elacestrant to the standard drug olaparib can help people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a BRCA gene mutation. About 176 participants will be randomly assigned to receive either the combination o…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: GBG Forschungs GmbH • Aim: Disease control
Last updated Jun 18, 2026 11:50 UTC
-
New combo therapy aims to control advanced breast cancer
Disease control Recruiting nowThis study tests a drug called alisertib combined with hormone therapy for people with a common type of advanced breast cancer (HR+, HER2-). The cancer has continued to grow despite at least two prior hormone treatments. The goal is to find the best dose of alisertib and see if t…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Puma Biotechnology, Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
New hope for Hard-to-Treat breast cancer: targeted drug trial begins
Disease control Recruiting nowThis early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New hope for tough breast cancer: experimental drug EP0062 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called EP0062, alone or with standard treatments, in people with a certain type of advanced breast cancer (AR+/HER2-) that has returned or spread. The main goals are to find the safest dose and see if it helps shrink tumors. About 95 adults a…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Ellipses Pharma • Aim: Disease control
Last updated Jun 12, 2026 12:05 UTC
-
Timing matters: menstrual cycle may influence breast cancer treatment choices
Knowledge-focused Recruiting nowThis study looks at how the menstrual cycle and preoperative hormone therapy affect a marker called Ki67 in women with early hormone-positive breast cancer. Researchers will also see if adding a genetic test (PAM50) changes treatment recommendations. About 504 women will particip…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Sponsor: University Hospital Tuebingen • Aim: Knowledge-focused
Last updated Jun 23, 2026 12:00 UTC